Current Status and Ongoing Development of Reversing Agents for Novel Oral Anticoagulants (NOACs)

E-ISSN： 2212-3962|8|1|2-9

ISSN： 1574-8901

Source： Recent Patents on Cardiovascular Drug Discovery, Vol.8, Iss.1, 2013-04, pp. : 2-9

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Non-Vitamin K Oral Anticoagulants (NOACs) A Review of Clinical Management and Laboratory Issues

Current Vascular Pharmacology, Vol. 14, Iss. 3, 2016-05 ,pp. : 220-236

Bentham Science Publishers

Access to resources Recommend Favorite

Novel oral Anticoagulants in Non-Valvular Atrial Fibrillation

Cardiovascular & Hematological Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Cardiovascular & Hematological Agents), Vol. 12, Iss. 1, 2014-04 ,pp. : 3-8

Bentham Science Publishers

Access to resources Recommend Favorite

Novel Oral Anticoagulants in Atrial Fibrillation: Update on Apixaban

Current Cardiology Reviews, Vol. 13, Iss. 1, 2016-11 ,pp. : 41-46

Bentham Science Publishers

Access to resources Recommend Favorite

Specific Antidotes in Development for Reversal of Novel Anticoagulants: A Review

Recent Patents on Cardiovascular Drug Discovery, Vol. 9, Iss. 1, 2014-06 ,pp. : 2-10

Bentham Science Publishers

Access to resources Recommend Favorite

Drug and dietary interactions of warfarin and novel oral anticoagulants: an update

By Nutescu Edith Chuatrisorn Ittiporn Hellenbart Erika

Journal of Thrombosis and Thrombolysis, Vol. 31, Iss. 3, 2011-04 ,pp. : 326-343

Springer Publishing Company

Access to resources Recommend Favorite